Renalytix shares fall 25% as revenues miss expectations Proactive uses images sourced from Shutterstock Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and Medicare-reimbursed kidneyintelX.dkd test for early-stage diabetic kidney disease, said full-year revenue is now expected to reach ...

Core Insights - BillionToOne has launched two new add-on applications, Northstar PGx and Northstar Select CH, to enhance the Northstar Select platform for liquid biopsy testing, which is designed for advanced solid tumors [1] Group 1: Product Launch and Features - Northstar PGx provides pharmacogenomic insights into key variants in DPYD and UGT1A1, which are critical for fluoropyrimidine and irinotecan-based therapies, helping inform treatment planning without extending turnaround time [1] - Northstar Select CH addresses clonal hematopoiesis, which can lead to false positives in cfDNA testing, achieving over 99% accuracy in distinguishing tumor-derived alterations from non-tumor findings [1] - The integration of these applications into the Northstar workflow allows for comprehensive insights from a single blood draw, enhancing clinical decision-making without adding complexity [1] Group 2: Clinical Validation and Performance - Northstar Select demonstrated superior performance in detecting clinically actionable alterations, identifying 51% more pathogenic single nucleotide variants and 109% more copy number variants compared to other liquid biopsy tests [1] - The assay showed 98% concordance with results from digital droplet PCR, validating its sensitivity and accuracy in clinical settings [1] Group 3: Industry Context and Implications - The launch reflects a commitment to improving oncologists' ability to select appropriate therapies, thereby avoiding ineffective treatments and potential chemotherapy toxicity [1] - Recent guidelines emphasize the importance of broader testing, which aligns with the capabilities of Northstar PGx and Northstar Select CH, supporting the trend towards personalized medicine in oncology [1]

Core Viewpoint - The Super Bowl advertisement by Hims & Hers has raised concerns regarding the reliability and ethical implications of its newly launched cancer-detection test, which aims to detect over 50 types of cancer before symptoms appear [1][2]. Product Overview - The cancer-detection test, developed by Grail Inc., is designed to identify hard-to-detect cancers such as pancreatic and ovarian, which currently lack routine screening options [2]. - The advertisement suggests that the test democratizes access to healthcare, providing the same opportunities for cancer detection to all individuals, regardless of their socioeconomic status [2]. Reliability Concerns - Critics have questioned the test's reliability, noting that Grail Inc. recommends follow-up medical testing to confirm any cancer diagnosis [3]. - Interim results indicate that the test detects approximately 40% of cancers, meaning it misses more than half of cases even when cancer is present [3]. Expert Opinions - Eric Topol from Scripps Research acknowledged that the test could be beneficial for individuals at high risk of cancer but cautioned that widespread use might lead to financial waste and misleading results [4]. Pricing and Accessibility - Hims & Hers plans to offer the test to subscribers of its $350 lab service at a price of $700, which is about a 25% discount from the manufacturer's list price [4]. Regulatory Status - Grail has sought approval from the FDA under the most stringent regulatory pathway for medical devices and diagnostics [5]. Financial Performance - Hims & Hers reported disappointing Q3 earnings, with an EPS of 6 cents, missing estimates, while revenue reached $598.97 million, exceeding expectations [6]. - The company has guided fourth-quarter revenue below consensus and adjusted its 2025 revenue outlook to align with analyst forecasts [6]. Market Performance - Hims & Hers is ranked in the 87th percentile for growth and the 7th percentile for value, indicating mixed performance [7]. - Over the past year, the stock has declined by 48.58%, closing at $23.02 after a 1.96% drop on the last trading day [7].

Core Insights - The initiative emphasizes that innovation in diagnostics must align with the needs of clinicians, laboratories, and patients to create value [1] - Expanding diagnostics in emerging markets requires trust, education, and strategies tailored to real clinical and operational realities [2] Training and Adoption - The program included scalable training and certification for commercial, technical, and clinical teams, enhancing product knowledge and technical confidence [2] - A training framework developed during the program was adopted by Abbott's global teams, indicating its effectiveness beyond Latin America [3] Sales and Operational Impact - The launch of a next-generation immunodiagnostic platform, combined with technical education and localized marketing, led to a 5% sales increase in key Latin American markets shortly after its introduction [4] - An ISE Training and Documentation initiative resulted in a 15% improvement in regional service KPIs, reduced technical complaints, and increased customer satisfaction [4] Professional Development and Recognition - The initiative trained and certified over 200 healthcare and diagnostics professionals and facilitated more than 100 successful diagnostic system installations across Latin America and the Caribbean [5] - Riaño received the National Research Award for her work on rotavirus genotyping in collaboration with the CDC, highlighting contributions to scientific research [5] Ongoing Commitment - Abbott Laboratories continues to invest in regional training, market development, and diagnostic innovation to enhance healthcare outcomes in emerging markets [6]

Core Insights - Quanterix (QTRX) has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test aimed at evaluating patients with cognitive symptoms for potential Alzheimer's disease, marking a significant step in the company's efforts to provide non-invasive diagnostic solutions for Alzheimer's [1][2]. Company Developments - The 510(k) submission is indicative of strong operational execution and is a crucial milestone for Quanterix in meeting the diagnostic needs related to Alzheimer's disease [2]. - The test utilizes Simoa technology to combine five biomarkers into a single readout, offering a comprehensive view of disease biology, which is expected to enhance diagnostic interpretability, especially in early disease stages [6][9]. - The submission is supported by clinical data from over 1,800 patients across three independent cohorts, demonstrating the test's potential effectiveness [6][10]. - The multi-analyte test has previously received FDA Breakthrough Device Designation, highlighting its potential to improve diagnosis for serious conditions like Alzheimer's [8]. Market Potential - The Alzheimer's disease diagnostics and treatment market was valued at $7.72 billion in 2025 and is projected to grow at a CAGR of 9% through 2032, driven by advancements in neuroimaging technologies, monoclonal antibodies, and AI integration in diagnostics [11]. - The pending FDA clearance for Quanterix's test could significantly expand its addressable market by facilitating broader adoption of non-invasive Alzheimer's diagnostics, particularly in earlier disease stages where clinical need is high [4]. Competitive Positioning - Quanterix's integrated multi-biomarker approach differentiates it from single-analyte competitors, potentially providing pricing power and long-term clinical relevance in Alzheimer's diagnosis and treatment decisions [4][9].

Core Viewpoint - Exact Sciences Corp. celebrates the passage of federal legislation that will enable Medicare coverage for multi-cancer early detection (MCED) tests, addressing a significant gap in cancer screening [1] Group 1: Legislative Impact - The new legislation establishes a pathway for Medicare to cover MCED tests, which is crucial for early cancer detection [1] - Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers that currently have no recommended screening [1] Group 2: Industry Context - Cancer remains the second leading cause of death in the U.S., highlighting the urgent need for improved screening methods [1]

Core Insights - Exact Sciences Corp. has achieved a significant milestone with its Oncotype DX Breast Recurrence Score® test, as over two million breast cancer patients globally have utilized the test to inform their treatment decisions [1] Company Overview - Exact Sciences Corp. is recognized as a leading provider of cancer screening and diagnostic tests [1] - The Oncotype DX Breast Recurrence Score® test is supported by more than two decades of clinical evidence, establishing it as a global standard-of-care [1]

Core Insights - ProPhase Labs has initiated a potential sale or strategic partnership process for its BE-Smart esophageal cancer risk stratification test, aiming to enhance liquidity and strengthen its balance sheet [1][2][7] - The company is also advancing its Crown Medical Collections initiative to recover unpaid and underpaid COVID-19 diagnostic testing claims, which could provide significant liquidity [8][12] BE-Smart Initiative - The objective of the BE-Smart initiative is to generate a meaningful liquidity event while facilitating broader clinical adoption through established industry platforms [2] - ProPhase has completed a comprehensive clinical and commercial dossier and is reaching out to over 70 potential acquirers and strategic partners across various medical fields [3] - BE-Smart is a CLIA-certified, CAP-accredited laboratory-developed test that identifies patients at elevated risk of progression from Barrett's esophagus to esophageal adenocarcinoma, with an estimated addressable market opportunity of up to $14 billion annually [4][6] Crown Medical Collections Initiative - The Crown Medical Collections initiative focuses on recovering unpaid and underpaid claims, with over 60% of claims being partially reimbursed rather than denied, which enhances the recovery profile [9][10] - The initiative is expected to attract interest from financing sources for potential recovery-based, non-recourse funding structures, which would be repaid solely from recovery proceeds [11][12] - The company believes that successful execution of this initiative could represent a significant liquidity event [12]

As filed with the Securities and Exchange Commission on February 2, 2026 Registration No. 333-293109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ CHECK-CAP LTD. (Exact name of registrant as specified in its charter) ____________________ | (State or other jurisdiction of | | --- | | incorporation or organization) | (Primary Standard Industrial Classification ...

Core Insights - IDEXX Laboratories reported strong fourth-quarter revenue growth driven by its companion animal diagnostics business, but shares fell more than 4% intraday as earnings narrowly missed expectations and guidance came in largely in line [1] Group 1: Financial Performance - Revenue increased 14% year over year to $1.09 billion, topping analyst estimates of $1.07 billion [1] - Adjusted earnings per share totaled $2.92, slightly below the consensus estimate of $2.93 [1] - Operating margin expanded 150 basis points year over year to 28.9%, while adjusted operating margin improved by 120 basis points [2] Group 2: Business Segments - The Companion Animal Group segment posted revenue growth of 15% to $998.5 million, with international markets expanding 17% [2] - Growth was driven by a 12% increase in CAG Diagnostics recurring revenue, which reached $849.7 million [2] - IDEXX's Water business also delivered solid performance, with revenue rising 12% to $50.5 million [3] Group 3: Future Projections - For 2026, IDEXX projected revenue of $4.63 billion to $4.72 billion and earnings per share of $14.29 to $14.80, largely in line with expectations [3] - Organic revenue growth is expected to range from 7% to 9%, with operating margin expansion of 40 to 90 basis points [3]